Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Research

• Publication date

  2005-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-04-4426PMID 16103076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

  2004cited by this paper
• Inducible, reversible, and stable RNA interference in mammalian cells

  2004cited by this paper
• Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts

  2004cited by this paper
• Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer

  2004cited by this paper
• HIF-1 and hypoxic response: the plot thickens.

  2004cited by this paper
• Development of a tightly regulated U6 promoter for shRNA expression

  2004cited by this paper
• Regulation of Transcription and Translation by Hypoxia

  2004cited by this paper
• Establishment of conditional vectors for hairpin siRNA knockdowns.

  2003cited by this paper
• In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats

  2003cited by this paper
• Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

  2003cited by this paper
• Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector

  2003cited by this paper
• Stable and controllable RNA interference: Investigating the physiological function of glutathionylated actin

  2003cited by this paper
• The hypoxic response of tumors is dependent on their microenvironment.

  2003cited by this paper
• Inducible shRNA expression for application in a prostate cancer mouse model.

  2003cited by this paper
• RNA interference

  2002cited by this paper
• RNA interference: the new somatic cell genetics?

  2002cited by this paper
• Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression

  2002cited by this paper
• Hypoxia — a key regulatory factor in tumour growth

  2002cited by this paper
• RNA interference--2001.

  2001cited by this paper
• RNA Interference and Small Interfering RNAs

  2001cited by this paper
• RNA interference: listening to the sound of silence

  2001cited by this paper
• Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth

  2000influential reference
• Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.

  2000cited by this paper
• RNA Interference

  2000cited by this paper
• Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.

  1999cited by this paper
• HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

  1998cited by this paper
• Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

  1998cited by this paper
• HIF‐1α is required for solid tumor formation and embryonic vascularization

  1998cited by this paper
• Insight Review Articles

  year unknowncited by this paper

• Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy.

  2025cites this paper
• The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

  2023cites this paper
• Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

  2023cites this paper
• Impact of RNAi-Targeted Silencing of Survivin and Hypoxia-Inducible Factor-1α on the Biological Behaviors of Gastric Cancer SGC-7901 Cells In Vitro

  2021cites this paper
• Tumor self-responsive upconversion nanomedicines for theranostic applications.

  2019cites this paper
• 5 Approaches in Gene Therapy of Cancer and Cardiovascular Diseases

  2018cites this paper
• Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives.

  2018cites this paper
• Pyruvate dehydrogenase kinase 1 and carbonic anhydrase IX targeting in hypoxic tumors.

  2018cites this paper
• Hypoxia Selectively Enhances Integrin α5β1 Receptor Expression in Breast Cancer to Promote Metastasis

  2017cites this paper
• Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome

  2017cites this paper
• Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours

  2016cites this paper
• Inducible RNAi system and its application in novel therapeutics

  2016cites this paper
• Co-delivery of HIF 1 a siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer

  2015cites this paper
• The Effect of Silencing HIF-1α Gene in BxPC-3 Cell Line on Glycolysis-Related Gene Expression, Cell Growth, Invasion, and Apoptosis

  2015cites this paper
• Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.

  2015cites this paper
• In vitro evaluation of anticancer properties of exopolysaccharides from Lactobacillus acidophilus in colon cancer cell lines

  2015cites this paper
• Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.

  2015cites this paper
• Manipulating the Tumor Microenvironment for Therapeutic Benefit

  2014cites this paper
• siRNA: novel therapeutics from functional genomics

  2014cites this paper
• The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.

  2014cites this paper
• Glioma: A Tale of Corticosteroids, Thiopurines and Proposed Novel AntiGlioma Small Molecules

  2014cites this paper
• Branching into RNAi: Synthesis, Characterization and Biology of Branch and Hyperbranch siRNAs

  2014cites this paper
• Cancer Cell Respiration: Hypoxia and pH in Solid Tumors

  2013cites this paper
• HYPOXIA-INDUCIBLE FACTOR (HIF)-1α AS A THERAPEUTICAL TARGET IN MYELOMA INDUCED ANGIOGENESIS AND BONE DESTRUCTION IN VITRO AND IN VIVO

  2013cites this paper
• Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis

  2013cites this paper
• Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300.

  2013cites this paper
• BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I

  2013cites this paper
• Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics

  2013cites this paper
• Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis

  2013cites this paper
• Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction

  2013cites this paper
• Collagen prolyl hydroxylases are essential for breast cancer metastasis.

  2013cites this paper
• Cell Death and Survival Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis

  2013cites this paper
• Design and in vitro activities of N -alkyl- N -[(8- R -2,2-dimethyl- 2H -chromen-6-yl)methyl]heteroarylsulfonamides, novel small molecule Hypoxia Inducible Factor-1 (HIF-1) pathway inhibitors and anti-cancer agents

  2013cites this paper
• Molecular and Cellular Pathobiology CollagenProlyl HydroxylasesAreEssential for BreastCancer Metastasis

  2013cites this paper
• Contribution of the Unfolded Protein Response to VEGF Expression

  2012cites this paper
• Cancer Therapy : Preclinical Arylsulfonamide KCN 1 Inhibits In Vivo Glioma Growth and Interfereswith HIF Signaling byDisrupting HIF-1 a Interaction with Cofactors p 300 / CBP

  2012cites this paper
• Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP

  2012cites this paper
• Targeting the metabolic microenvironment of tumors.

  2012cites this paper
• Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

  2012cites this paper
• Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide

  2012cites this paper
• Ascorbic acid in cancer chemoprevention: translational perspectives and efficacy.

  2012cites this paper
• Design of Synthetic shRNAs for Targeting Hepatitis C: A New Approach to Antiviral Therapeutics

  2012cites this paper
• Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications.

  2012cites this paper
• Approaches in Gene Therapy of Cancer and Cardiovascular Diseases

  2011cites this paper
• Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation

  2011influential citation
• A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors.

  2011cites this paper
• Combined lentiviral and RNAi technologies for the delivery and permanent silencing of the hsp25 gene.

  2011cites this paper
• Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery

  2011cites this paper
• Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma

  2011cites this paper
• Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective

  2011cites this paper
• Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor

  2011cites this paper
• Regulation of the Thioredoxin System under Hypoxia and Different Oxygen Conditions

  2011cites this paper
• Hydroxyalkylbenzyle-pyrazoles et leur utilisation pour le traitement de maladies hyperprolifératives et angiogéniques

  2011cites this paper
• Tumorigenesis and Neoplastic Progression Hypoxia Inducible Factor-1 Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death

  2010cites this paper
• HIF-1alpha and cancer therapy.

  2010cites this paper
• Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1β) activity is required more during early than late tumor growth

  2010cites this paper
• oxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Distinct and Functionally Overlapping Roles in R l Squamous Cell Carcinoma

  2010cites this paper
• Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo

  2010cites this paper
• Toxicogenomics in Preclinical Development

  2010cites this paper
• Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

  2010cites this paper
• Hypoxia response pathway in border cell migration

  2010cites this paper
• HIF1-positive and HIF1-negative glioblastoma cells compete in vitro but cooperate in tumor growth in vivo.

  2010cites this paper
• Hypoxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Play Distinct and Functionally Overlapping Roles in Oral Squamous Cell Carcinoma

  2010cites this paper
• In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence.

  2010cites this paper
• Targeted Knockdown of SEPT9_v1 Inhibits Tumor Growth and Angiogenesis of Human Prostate Cancer Cells Concomitant with Disruption of Hypoxia-Inducible Factor-1 Pathway

  2010cites this paper
• Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity.

  2010cites this paper
• Development of an oncolytic Herpes Simplex Virus using a tumor-specific HIF-responsive promoter

  2010cites this paper
• Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and anti-tumor efficacy

  2010cites this paper
• Cancer therapy by targeting hypoxia-inducible factor-1.

  2010cites this paper
• Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets

  2009cites this paper
• Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

  2009cites this paper
• The Warburg Effect and Its Role in Cancer Detection and Therapy

  2009cites this paper
• Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads

  2009cites this paper
• Suppression of graft-versus-host disease after adoptive infusion of alloreactive NK cells induced by silencing Ly49C gene in mice.

  2009cites this paper
• Human cancers converge at the HIF-2α oncogenic axis

  2009cites this paper
• Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice.

  2009cites this paper
• Silencing of HIF-1alpha by RNA interference in human glioma cells in vitro and in vivo.

  2009cites this paper
• Factors interacting with HIF-1alpha mRNA: novel therapeutic targets.

  2009cites this paper
• Inhibition of telomerase and hypoxia-inducible factor-1 in human glioblastoma multiforme

  2009cites this paper
• Role of Myeloid Hypoxia-Inducible Factor-1alpha in the Tumor Microenvironment A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Biology

  2008cites this paper
• The controversial place of vitamin C in cancer treatment.

  2008cites this paper
• Cellular adaptation to hypoxia and reoxygenation through gene specific mRNA translation

  2008cites this paper
• Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1α expression in tumor cells and hepatocytes

  2008cites this paper
• RNA Interference and cyclooxygenase-2 (COX-2) regulation in colon cancer cells

  2008cites this paper
• Role of myeloid Hypoxia-Inducible Factor-1alpha in the tumor microenvironment - eScholarship

  2008cites this paper
• Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer.

  2008cites this paper
• A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation

  2008cites this paper
• Effects of lentivirus-mediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells

  2008cites this paper
• A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

  2008cites this paper
• RNAi: An emerging field of molecular research

  2008cites this paper
• The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer.

  2008cites this paper
• Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.

  2008cites this paper
• RNA interference: the story of gene silencing in plants and humans.

  2008cites this paper
• PX‐478, an inhibitor of hypoxia‐inducible factor‐1α, enhances radiosensitivity of prostate carcinoma cells

  2008cites this paper
• Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung

  2008cites this paper
• Targeting hypoxia cell signaling for cancer therapy

  2007cites this paper
• Transgenic models to understand hypoxia-inducible factor function.

  2007cites this paper
• Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model.

  2007cites this paper
• Silencing of Hypoxia Inducible Factor-1α by RNA Interference Attenuates Human Glioma Cell Growth In vivo

  2007cites this paper
• Defining the optimal parameters for hairpin-based knockdown constructs.

  2007cites this paper